(ZEAL) Zealand Pharma - Ratings and Ratios

Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0060257814

ZEAL: Medicines, Peptides, Hormones, Injectors, Syringes, Drugs

Zealand Pharma A/S is a biotechnology company based in Denmark, specializing in the discovery, development, and commercialization of innovative peptide-based therapies. Founded in 1997 and headquartered in Søborg, the company has established itself as a leader in addressing unmet medical needs, particularly in gastrointestinal and metabolic diseases. Zealand Pharmas approach leverages the versatility of peptides, which are highly specific and can be engineered for targeted therapeutic effects. This focus has led to a pipeline of promising candidates, with several in advanced clinical stages.

The companys lead product, Dasiglucagon, is a synthetic glucagon analog designed for the treatment of severe hypoglycemia. It is available as a convenient single-use autoinjector or syringe, offering a practical solution for patients. Additionally, Zealand Pharma is advancing Dasiglucagon in bi-hormone artificial pancreas systems, combining insulin and glucagon to mimic natural pancreatic function. This innovation holds potential for improving glycemic control in diabetes management. Currently, Dasiglucagon is in Phase III clinical trials for congenital hyperinsulinism, a rare condition causing severe hypoglycemia in infants and children.

Another key candidate in Zealand Pharmas pipeline is glepaglutide, a long-acting GLP-2 analog. It is being developed for short bowel syndrome, a condition where patients struggle with nutrient absorption due to a shortened intestinal tract. Glepaglutide aims to enhance intestinal function and reduce the need for parenteral nutrition. The compound is also in Phase III clinical trials, with results expected to further validate its therapeutic potential. Zealand Pharmas strategic focus on gastrointestinal and metabolic disorders positions it well to address critical patient needs while offering significant opportunities for growth in specialized therapeutic areas.

From a financial perspective, Zealand Pharma A/S is listed under the ticker symbol ZEAL on the CO exchange. The company has a market capitalization of approximately 51,960M DKK, reflecting its established position in the biotechnology sector. The price-to-book ratio stands at 5.82, indicating a premium valuation relative to its book value. The price-to-sales ratio of 675.96 highlights the markets expectation of future revenue growth, driven by its pipeline

Additional Sources for ZEAL Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ZEAL Stock Overview

Market Cap in USD 5,671m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception

ZEAL Stock Ratings

Growth 5y 43.9%
Fundamental -
Dividend 0.0%
Rel. Strength -17.8
Analysts -
Fair Price Momentum 413.46 DKK
Fair Price DCF -

ZEAL Dividends

No Dividends Paid

ZEAL Growth Ratios

Growth Correlation 3m -66.6%
Growth Correlation 12m -11.2%
Growth Correlation 5y 61.7%
CAGR 5y 16.98%
CAGR/Max DD 5y 0.23
Sharpe Ratio 12m -0.61
Alpha -35.19
Beta 0.532
Volatility 63.35%
Current Volume 746.5k
Average Volume 20d 391.6k
What is the price of ZEAL stocks?
As of April 02, 2025, the stock is trading at DKK 465.80 with a total of 746,497 shares traded.
Over the past week, the price has changed by -17.63%, over one month by -23.64%, over three months by -36.02% and over the past year by -29.05%.
Is Zealand Pharma a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Zealand Pharma (CO:ZEAL) is currently (April 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 43.94 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ZEAL as of April 2025 is 413.46. This means that ZEAL is currently overvalued and has a potential downside of -11.24%.
Is ZEAL a buy, sell or hold?
Zealand Pharma has no consensus analysts rating.
What are the forecast for ZEAL stock price target?
According to ValueRays Forecast Model, ZEAL Zealand Pharma will be worth about 453.4 in April 2026. The stock is currently trading at 465.80. This means that the stock has a potential downside of -2.67%.
Issuer Forecast Upside
Wallstreet Target Price 955.9 105.2%
Analysts Target Price - -
ValueRay Target Price 453.4 -2.7%